Anika Therapeutics to Webcast Presentation at Canaccord Adams Musculoskeletal Conference
BEDFORD, Mass. --(BUSINESS WIRE)--Feb. 19, 2009-- Anika Therapeutics, Inc. (NASDAQ:ANIK) today announced that Charles Sherwood , president and chief executive officer, will be presenting at the Canaccord Adams Musculoskeletal Conference on Tuesday, February 24, 2009 at 10:20 a.m. PT ( 1:20 p.m. ET ). A live audio webcast of the presentation may be accessed via the Internet at: http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2550240. In addition, the presentation will be available live at the “Investors” section of Anika’s website at www.anikatherapeutics.com.
Within the presentation Dr. Sherwood will discuss the current state of the business, including the Company’s joint health product franchise and related U.S. clinical trial for MONOVISC™, a single-injection treatment for osteoarthritis.
About Anika Therapeutics, Inc.
Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. Anika’s products include ORTHOVISC®, a treatment for osteoarthritis of the knee available internationally and marketed in the U.S. by DePuy Mitek; HYVISC®, a treatment for equine osteoarthritis marketed in the U.S. by Boehringer Ingelheim Vetmedica, Inc.; the ELEVESS™ family of aesthetic dermatology products for facial wrinkles, scar remediation and lip augmentation; AMVISC®, AMVISC® Plus, STAARVISC™-II and Shellgel™ injectable viscoelastic HA products for ophthalmic surgery; INCERT®, an HA-based anti-adhesive for surgical applications; ORTHOVISC® mini a treatment for osteoarthritis targeting small joints and available in Europe; MONOVISC™ a single-injection osteoarthritis product based on our proprietary cross-linking technology and also available in Europe; and next generation products for joint health and aesthetic dermatology based on the Company’s proprietary, chemically modified HA.
Source: Anika Therapeutics, Inc.
Anika Therapeutics, Inc.
Charles H. Sherwood, Ph.D., 781-457-9000
Kevin W. Quinlan, 781-457-9000